EUVIMEDEUVIMED entdecken
Crossref

Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis

Felipe Soto-Lanza, Lydia Glick, Colin Chan, Linda Zhong, Nathaniel Wilson, Saadia Faiz, Saumil Gandhi, Aung Naing, John V Heymach, Vickie R Shannon, Maria Franco-Vega, Zhongxing Liao und 6 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.07.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Felipe Soto-Lanza und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Division of Internal Medicine, MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pneumonia, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Despite known short-term mortality risk of immune checkpoint inhibitor (ICI) pneumonitis, its impact on 1-year mortality, long-term pulmonary function, symptom persistence, and radiological resolution remains unclear. METHODS: We retrospectively analyzed 71 nonsmall cell lung cancer (NSCLC) patients treated with anti-PD(L)1 monoclonal antibodies between 2018-2021, who developed pneumonitis. Clinical and demographic covariates were collected from electronic medical record. Cox regression assessed associations with mortality, while logistic regression evaluated associations with persistent symptoms, hypoxemia, and radiological resolution. RESULTS: Steroid-refractory pneumonitis (hazard ratio [HR] = 15.1, 95% confidence interval [95% CI]:3.9-57.8, P < .0001) was associated with higher 1-year mortality compared to steroid-responsive cases. However, steroid-resistant (odds ratio [OR] = 1.4, 95% CI: 0.4-5.1, P = .58) and steroid-dependent (OR = 0.4, 95% CI: 0.1-1.2, P = .08) pneumonitis were not. Nonadenocarcinoma histology (OR = 6.7, 95% CI: 1.6-46.6, P = .01), grade 3+ pneumonitis (OR = 4.6, 95% CI: 1.3-22.7, P = .03), and partial radiological resolution (OR = 6.3, 95% CI: 1.8-23.8, P = .004) were linked to increased pulmonary symptoms after pneumonitis resolution. Grade 3+ pneumonitis (OR = 8.1, 95% CI: 2.3-31.5, P = .001) and partial radiological resolution (OR = 5.45, 95% CI: 1.29-37.7, P = .03) associated with residual hypoxemia. Nonadenocarcinoma histology (OR = 3.6, 95% CI: 1.01-17.6, P = .06) and pretreatment ILAs (OR = 4.8, 95% CI: 1.14-33.09, P = .05) were associated with partial radiological resolution. CONCLUSIONS: Steroid refractory pneumonitis increases 1-year mortality in NSCLC patients. Pretreatment ILAs may signal predisposition to fibrosis-related outcomes, seen as partial resolution, which in turn is associated with postresolution symptoms and residual hypoxemia. These findings offer insights for identifying patients at risk of adverse outcomes post-pneumonitis resolution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPneumoniaLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansMaleFemaleRetrospective StudiesAgedMiddle AgedFollow-Up StudiesAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

Cancer survivorshipInterstitial lung abnormalitiesRadiological resolutionSteroid-refractorySteroid-resistant

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Division of Internal Medicine, MD Anderson Cancer Center, Houston, TX.
  • Department of Internal Medicine, Baylor College of Medicine, Houston, TX.
  • Texas A&M University School of Medicine, Houston, TX.
  • Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX.
  • Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
  • Department of Thoracic Radiation Oncology, Division of Radiation Oncology, MD Anderson Cancer Center, Houston, TX.

Förderung

  • NCI NIH HHS

Zitieren

APA

Soto-Lanza, F., Glick, L., Chan, C., Zhong, L., Wilson, N., Faiz, S., Gandhi, S., Naing, A., Heymach, J. V., Shannon, V. R., Franco-Vega, M., Liao, Z., Lin, S. H., Palaskas, N. L., Wu, J., Shroff, G. S., Altan, M., & Sheshadri, A. (2024). Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.07.017

Vancouver

Soto-Lanza F, Glick L, Chan C, Zhong L, Wilson N, Faiz S, et al. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.07.017

BibTeX
@article{SotoLanza2024,
  author = {Soto-Lanza, Felipe and Glick, Lydia and Chan, Colin and Zhong, Linda and Wilson, Nathaniel and Faiz, Saadia and Gandhi, Saumil and Naing, Aung and Heymach, John V and Shannon, Vickie R and Franco-Vega, Maria and Liao, Zhongxing and Lin, Steven H and Palaskas, Nicolas L and Wu, Jia and Shroff, Girish S and Altan, Mehmet and Sheshadri, Ajay},
  title = {Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.07.017}
}
Kostenlos starten →